Hale and Dorr Clients Nominated for the Annual Breakthrough Alliance Award for the Sixth Year

Download IconDownload Print IconPrint

Hale and Dorr Clients Nominated for the Annual Breakthrough Alliance Award for the Sixth Year

Firm News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
For companies in the life sciences sphere, licensing intellectual property and establishing strategic alliances are critical. WilmerHale’s experienced licensing lawyers shepherd biotech, pharmaceutical, healthcare and medical device clients of all sizes through the complex transactions that make their businesses possible, including a broad range of licensing, collaboration, strategic alliance and joint venture agreements. Our attorneys also excel at brokering manufacturing and supply agreements, contract research and development agreements, distribution and commercialization services agreements, and material transfer and confidentiality agreements. They also frequently represent life sciences clients as they license patents—often the foundations of their companies—from, and sponsor research at, leading academic institutions across the United States and Europe. Backed not only by their own experience but also the deep well of knowledge possessed by the firm’s patent, tax, antitrust and EU competition lawyers, our transactional attorneys are ready to handle even the most multifaceted matters. Our team helps clients protect their innovations, forge strategic alliances, and successfully navigate a complex, dynamic industry.
Our clients in the ever-changing and fiercely competitive hardware, software, IT and services industries depend on us to strategize and negotiate transactions that take advantage of opportunities now while protecting their innovations and preserving flexibility for the future. We structure, negotiate and draft all types of licensing, distribution, product development, joint venture and strategic alliance agreements for these clients, often drawing on the deep experience of WilmerHale’s unique capabilities in regulatory, intellectual property, corporate and tax law. We represent both mature and emerging companies with business models centered around offering software and/or professional services relating to analyzing and extracting insights from large data sets. We frequently draft and negotiate data license agreements, software-as-a-service (SaaS) agreements, website terms and other services agreements in which data is the core subject of the license. We also advise technology clients on big data issues that arise in outsourcing, joint venture and other transactional matters. Our attorneys keep a close watch on internet-related legislative and regulatory developments in the United States, the European Union and elsewhere, and leverage our up-to-the-minute knowledge to advise clients in areas such as data privacy and security, copyright infringement, and export restrictions.

For the sixth year in the eight year history of the award, Hale and Dorr LLP has been counsel to at least one nominee for the Breakthrough Alliance Award sponsored by Recombinant Capital—an award given for the best and most innovative practices in drafting and negotiating alliances between biotechnology and pharmaceutical companies. In three of the past seven years in which the award was given, clients of Hale and Dorr took the award home. This year, three of the five nominees are Hale and Dorr clients.

Recombinant Capital annually nominates biotech-pharma alliances as the breakthrough deals of the previous year. The award is bestowed upon the alliance that receives the most votes by biotech and pharma business development and licensing executives.

Hale and Dorr has served as counsel to three of the five Alliance Award nominees this year: Idenix in the agreement with Novartis, focused on viral drugs and worth up to $862 million; Millennium Pharmaceuticals in the potential $500 million marketing deal for Velcade (bortezomib), a proteasome inhibitor for multiple myeloma with Ortho Biotech Products LP, a Johnson & Johnson company; and Eyetech Pharmaceuticals in a potential $750 million deal with Pfizer Inc., centered on developing and commercializing Macugen, Eyetech’s lead candidate for age-related macular degeneration and diabetic macular edema.

“We are delighted our clients continue to receive this distinct recognition by their peers in the biotechnology and pharmaceutical industry. Competition has remained fierce over the past seven years—and we expect that competition among the 2004 nominees will be no exception.” said Steven Singer, co-chair of the Life Sciences Group at Hale and Dorr.

The eighth annual Breakthrough Alliance Award will be presented at a gala ceremony on the evening of April 6th during the Allicense 2004 conference in San Francisco.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel